Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Dermatology and Therapy
Published in: Dermatology and Therapy 4/2019

Open Access 01-12-2019 | Alopecia Areata | Review

Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata

Authors: Ana M. Montilla, Francisco Gómez-García, Pedro J. Gómez-Arias, Jesús Gay-Mimbrera, Jorge Hernández-Parada, Beatriz Isla-Tejera, Juan Ruano

Published in: Dermatology and Therapy | Issue 4/2019

Login to get access

Abstract

Introduction

The JAK/STAT signaling pathway is involved in the immune-mediated inflammatory skin diseases atopic dermatitis (AD), vitiligo, and alopecia areata (AA), and represents a potential target when developing treatments. So far, no drugs targeting this pathway have been approved for the treatment of dermatological diseases. We reviewed the use of drugs blocking the JAK/STAT pathway in the aforementioned diseases.

Methods

An a priori protocol was published. We used Joanna Briggs Institute Reviewer’s Manual methodology to conduct the review and PRISMA Extension for Scoping Review (PRISMA-ScR) to report results. MEDLINE, EMBASE, CINAHL, Scopus, and Web of Science databases were searched in a three-step approach on April 2019 by two researchers.

Results

Ninety-six mainly multicenter observational studies were included (66, 10, and 20 studies on AA, vitiligo, and AD, respectively). Tofacitinib and ruxolitinib were mainly used for the three diseases, and also upadacitinib, abrocitinib, baricitinib, cerdulatinib, delgocitinib, gusacitinib for AD, and baricitinib, PF-06700841, and PF-06651600 for AA. All patients with AD improved, whereas patients with vitiligo and patients with AA showed varied responses, including unresponsive cases. The safety profiles were similar for all drugs and diseases, mainly comprising mild or no adverse events.

Conclusions

Evidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality.
Appendix
Available only for authorised users
Literature
1.
Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45:701–9.PubMedPubMedCentralCrossRef
2.
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675–82.PubMedPubMedCentralCrossRef
3.
Chiang A, Ortenzio F, Juhasz MLW, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep. 2018;4:733–6.PubMedPubMedCentralCrossRef
4.
McMichael AJ, Pearce DJ, Wasserman D, et al. Alopecia in the United States: outpatient utilization and common prescribing patterns. J Am Acad Dermatol. 2007;57(Suppl):S49–51.PubMedCrossRef
5.
Mirzoyev S, Davis M, Torgerson R. Incidence of alopecia areata in Olmsted County, Minnesota 1990–2009. J Am Acad Dermatol. 2013;8(4S1):AB106.
6.
Hedayat K, Karbakhsh M, Ghiasi M, et al. Quality of life in patients with vitiligo: a cross-sectional study based on Vitiligo Quality of Life index (VitiQoL). Health Qual Life Outcomes. 2016;14:86.PubMedPubMedCentralCrossRef
7.
Rencz F, Gulácsi L, Péntek M, Wikonkál N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561–71.PubMedCrossRef
8.
Andersen L, Nyeland ME, Nyberg F. Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the US. Br J Dermatol. 2019. https://​doi.​org/​10.​1111/​bjd.​18451
9.
Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signalling pathway. J Cells Sci. 2009;117:1281–3.CrossRef
10.
11.
Schwartz DM, Bonelli M, Gadina M, O’Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.PubMedCrossRef
12.
13.
Jesson MI, Kishore N, Dowty ME, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186:4234–43.PubMedCrossRef
14.
Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri Kashani M, Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatol Treat. 2017;28:476–83.CrossRef
15.
Welsch K, Holstein J, Laurence A, Ghoreschi K. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 2017;47:1096–107.PubMedCrossRef
16.
17.
Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Pharm. 2012;69:2120.
18.
Colquhoun HL, Levac D, O’Brien KK, et al. Scoping reviews: time for clarity in definition, methods and reporting scoping reviews: time for clarity in definition. J Clin Epidemiol. 2014;67:1291–4.PubMedCrossRef
19.
Gómez-García F, Gómez-Arias PJ, Hernandez J, et al. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ Open. 2019;9(5):e028303.PubMedPubMedCentralCrossRef
20.
The Joanna Briggs Institute. Joanna Briggs Institute reviewers’ manual 2015: methodology for JBI scoping reviews. Adelaide: Joanna Briggs Inst.; 2015.
21.
Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169:467–73.PubMedCrossRef
22.
Reich K, Guttman-Yassky E, Beck LA, Hu X, Pangan AL, Teixeira HD. Early response to upadacitinib in moderate-to-severe atopic dermatitis: results from a phase 2B randomized, placebo-controlled trial. Allergy Eur J Allergy Clin Immunol. 2018;73(Suppl. 105):76.
23.
Morris GM, Nahmias ZP, Kim BS. Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor. JAAD Case Rep. 2018;4(6):515–7.PubMedPubMedCentralCrossRef
24.
De Bruin-Weller MS, Forman SB, Bodhani A, et al. Effects of upadacitinib on atopic dermatitis signs, symptoms and patient-reported outcomes from a phase IIb randomized, placebo-controlled trial. Br J Dermatol. 2018;179(1):e13.
25.
Nakagawa H, Nemoto O, Yamada H, Nagata T, Ninomiya N. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45(6):701–9.PubMedPubMedCentralCrossRef
26.
Turvey SE, Del Bel K, Ragotte R, McKinnon M. Characterization and successful treatment of a novel autosomal dominant immune dysregulatory syndrome caused by a JAK1 gain-of function mutation. J Clin Immunol. 2018;38(3):435–6.
27.
Nakagawa H, Nemoto O, Igarashi A, Nagata T. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424–32.PubMedCrossRef
28.
Vu M, Heyes C, Robertson SJ, Varigos GA, Ross G. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017;58:99–100.
29.
Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–11.PubMedCrossRef
30.
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol. 2015;73(3):395–9.PubMedCrossRef
31.
Owens S, Liu H, Sun K, Venturanza M, Kuligowski M, Howell M. 998-Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients. J Investig Dermatol. 2019;139(5):S173.CrossRef
32.
Song T, Pavel AB, Peng X, et al. 1024-Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates. J Investig Dermatol. 2019;139(5):S177.CrossRef
33.
Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80:913.e9–921.e9.CrossRef
34.
Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol. 2019. https://​doi.​org/​10.​1111/​bjd.​17932.
35.
Beck LA, Silverberg JI, Grebe K, et al. Eosinophil count and serum immunoglobulin e levels in atopic dermatitis: analysis of upadacitinib phase 2 study findings. J Allergy Clin Immunol. 2019;143:AB125.CrossRef
36.
Owens S, Howell MD. Ruxolitinib cream suppresses Th2 inflammation in adult patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:AB128.CrossRef
37.
Beck L, Hong C, Hu X, et al. Upadacitinib effect on pruritus in moderate-to-severe atopic dermatitis; from a phase 2B randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2018;121:S21.CrossRef
38.
Purohit VS, Ports WC, Wang C, Riley S. Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning. J Clin Pharmacol. 2019;59:811–20.PubMedCrossRef
39.
Piscitelli S, Lee J, McHale K, et al. Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis. Exp Dermatol. 2018;27:S2.
40.
Gooderham M, Forman S, Bissonnette R, et al. The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD). J Investig Dermatol. 2018;138:S94.CrossRef
41.
Simpson E, Wollenberg A, Bissonnette R, et al. Effects of the oral Janus kinase 1 (JAK1) inhibitor PF-04965842 on patient-reported outcomes (PROs) in adults with moderate to severe atopic dermatitis (AD). J Investig Dermatol. 2018;138:S88.CrossRef
42.
Joshipura D, Alomran A, Zancanaro P, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 2018;78(6):1205.e1–1207.e1.CrossRef
43.
Photiou L, Sinclair R. An open label study of tofacitinib in the treatment of vitiligo. Australas J Dermatol. 2018;59:93.
44.
Kim SR, Heaton H, Liu LY, King BA. Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy. JAMA Dermatol. 2018;154(3):370–1.PubMedCrossRef
45.
Joshipura D, Plotnikova N, Goldminz A, et al. Importance of light in the treatment of vitiligo with JAK-inhibitors. J Dermatol Treat. 2018;29(1):98–9.CrossRef
46.
Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675.e1–682.e1.CrossRef
47.
Li S, Huang V. 2% topical tofacitinib cream in the treatment of vitiligo vulgaris. Pigment Cell Melanoma Res. 2017;30:e27–137.
48.
Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib. J Am Acad Dermatol. 2017;76(6):1054.e1–1060.e1.CrossRef
49.
Vu M, Heyes C, Robertson SJ, Varigos GA, Ross G. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo. Clin Exp Dermatol. 2017;42(8):942–4.PubMedCrossRef
50.
Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74(2):370–1.PubMedCrossRef
51.
Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110–2.PubMedCrossRef
52.
Chiang A, Ortenzio F, Juhasz MLW, Yu V, Mesinkovska NA. Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: a case report and review of the literature. JAAD Case Rep. 2018;4:733–6.PubMedPubMedCentralCrossRef
53.
Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Investig Dermatol. 2018;138(7):1539–45.PubMedCrossRef
54.
Putterman E, Castelo-Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis. J Am Acad Dermatol. 2018;78(6):1207.e1–1209.e1.CrossRef
55.
Photiou L, Sinclair R. An open label study of tofacitinib in the treatment of alopecia areata. Poster Presentations. Australas J Dermatol. 2018;59:92–3.
56.
Lee JS, Huh CH, Kwon O, Yoon HS, Cho S, Park HS. Nail involvement in patients with moderate-to-severe alopecia areata treated with oral tofacitinib. J Dermatol Treat. 2018;29:819–22.CrossRef
57.
Ramot Y, Zlotogorski A. Complete regrowth of beard hair with ruxolitinib in an alopecia universalis patient. Skin Appendage Disord. 2018;4(2):122–4.PubMedCrossRef
58.
Liu LY, Craiglow BG, King BA. Successful treatment of moderate-to-severe alopecia areata improves health-related quality of life. J Am Acad Dermatol. 2018;78(3):597.e2–599.e2.CrossRef
59.
Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403.e1–404.e1.CrossRef
60.
Patel NU, Oussedik E, Grammenos A, Pichardo-Geisinger R. A case report highlighting the effective treatment of alopecia universalis with tofacitinib in an adolescent and adult patient. J Cutan Med Surg. 2018;22(4):439–42.PubMedCrossRef
61.
Bokhari L, Sinclair R. Treatment of alopecia universalis with topical Janus kinase inhibitors—a double blind, placebo, and active controlled pilot study. Int J Dermatol. 2018;57(12):1464–70.PubMedCrossRef
62.
Park H-S, Kim M-W, Lee JS, et al. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: a case series. J Am Acad Dermatol. 2017;77(5):978–80.PubMedCrossRef
63.
Vandiver A, Girardi N, Alhariri J, Garza LA. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring. Int J Dermatol. 2017;56(8):833–5.PubMedPubMedCentralCrossRef
64.
Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–70.PubMedCrossRef
65.
Deeb M, Beach RA. A case of topical ruxolitinib treatment failure in alopecia areata. J Cutan Med Surg. 2017;21(6):562–3.PubMedCrossRef
66.
Patel N, Oussedik E, Pichardo-Geisinger RO, Feldman S. Efficacy of tofacitinib in pediatric alopecia universalis. J Am Acad Dermatol. 2017;76(6):AB121.CrossRef
67.
68.
Strazzulla LC, Avila L, Lo Sicco K, Shapiro J. Image Gallery: treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections. Br J Dermatol. 2017;176(6):e125.PubMedCrossRef
69.
Ibrahim O, Hogan S, Piliang M, Bergfeld W. Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: a retrospective chart review. J Investig Dermatol. 2017;137(5):S65.CrossRef
70.
Kim BY, Kim HS. Successful hair regrowth in a Korean patient with alopecia universalis following tofacitinib treatment. Singap Med J. 2017;58(5):279–80.CrossRef
71.
Castelo-Soccio L. Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis. J Am Acad Dermatol. 2017;76(4):754–5.PubMedCrossRef
72.
Mrowietz U, Gerdes S, Gläser R, Schröder O. Successful treatment of refractory alopecia areata universalis and psoriatic arthritis, but not of plaque psoriasis with tofacitinib in a young woman. Acta Derm Venereol. 2017;97(2):283–4.PubMedCrossRef
73.
Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22–8.PubMedCrossRef
74.
Salman A, Sarac G, Ergun T. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature. Dermatol Online J. 2017;23(7).
75.
Erduran F, Adışen E, Aksakal AB. Excellent response to tofacitinib treatment in a patient with alopecia universalis. Acta Dermatovenerol Alp Pannonica Adriat. 2017;26(2):47–9.PubMed
76.
Scheinberg M, Ferreira SB. Reversal of alopecia universalis by tofacitinib: a case report. Ann Intern Med. 2016;165(10):750–1.PubMedCrossRef
77.
Liu LY, King BA, Craiglow BG. Tofacitinib for the treatment of alopecia areata in the pediatric population. . Society for Pediatric Dermatology 42nd Annual Meeting Poster Presentations July 14–17, 2016, Minneapolis, Minnesota. Pediatr Dermatol. 2016;33(6):708–9.
78.
Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.PubMedPubMedCentralCrossRef
79.
Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.PubMedPubMedCentralCrossRef
80.
Ferreira SB, Scheinberg M, Steiner D, Steiner T, Bedin GL, Ferreira RB. Remarkable improvement of nail changes in alopecia areata universalis with 10 months of treatment with tofacitinib: a case report. Case Rep Dermatol. 2016;8(3):262–6.PubMedPubMedCentralCrossRef
81.
Jabbari A, Nguyen N, Cerise JE, et al. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers. Exp Dermatol. 2016;25(8):642–3.PubMedPubMedCentralCrossRef
82.
Abramovits W, Carviel JL, Gupta A. Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study. J Am Acad Dermatol. 2016;74(5):AB175.CrossRef
83.
Silvestri F, Rogato A, Mestroni R. Ruxolitinib for the treatment of alopecia areata. Ital J Med. 2016;10(Suppl. 2):108.
84.
Craiglow BG, Tavares D, King BA. Topical ruxolitinib for the treatment of alopecia universalis. JAMA Dermatol. 2016;152(4):490–1.PubMedCrossRef
85.
Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152(4):492–3.PubMedCrossRef
86.
Anzengruber F, Maul JT, Kamarachev J, Trüeb RM, French LE, Navarini AA. Transient efficacy of tofacitinib in alopecia areata universalis. Case Rep Dermatol. 2016;8(1):102–6.PubMedPubMedCentralCrossRef
87.
Gupta AK, Carviel JL, Abramovits W. Efficacy of tofacitinib in treatment of alopecia universalis in two patients. J Eur Acad Dermatol Venereol. 2016;30(8):1373–8.PubMedCrossRef
88.
Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–5.PubMedPubMedCentralCrossRef
89.
Pieri L, Guglielmelli P, Vannucchi AM. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol. 2015;90(1):82–3.PubMedCrossRef
90.
91.
Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–90.PubMedCrossRef
92.
Shivanna CB, Shenoy C, Priya RA. Tofacitinib (selective Janus kinase inhibitor 1 and 3): a promising therapy for the treatment of alopecia areata: a case report of six patients. Int J Trichology. 2018;10(3):103–7.PubMedPubMedCentralCrossRef
93.
Guttman-Yassky E, Pavel AB, Page K, et al. Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1). J Investig Dermatol. 2019;139(5):S94.CrossRef
94.
Lee JS, Yoon HS, Cho S, Park HS. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata. J Dermatol. 2019;46(4):e139–40.PubMedCrossRef
95.
Dai YX, Chen CC. Tofacitinib therapy for children with severe alopecia areata. J Am Acad Dermatol. 2019;80(4):1164–6.PubMedCrossRef
96.
Rachubinski AL, Estrada BE, Norris D, Dunnick CA, Boldrick JC, Espinosa JM. Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata. JAAD Case Rep. 2019;5(4):365–7.PubMedPubMedCentralCrossRef
97.
Gordon SC, Abudu M, Zancanaro P, Ko JM, Rosmarin D. Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2019;33(4):e156–7.PubMedCrossRef
98.
Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. J Am Acad Dermatol. 2019;80(2):566–8.PubMedCrossRef
99.
Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatology. 2019;235(2):130–6.PubMedCrossRef
100.
Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. J Am Acad Dermatol. 2019;80(2):568–70.PubMedCrossRef
101.
Serdaroğlu S, Engin B, Çelik U, et al. Clinical experiences on alopecia areata treatment with tofacitinib: a study of 63 patients. Dermatol Ther. 2019;32(3):e12844.PubMedCrossRef
102.
Ruiz-Villaverde R, Cuenca-Barrales C, Linares-Gonzalez L, Ródenas-Herranz T. Alopecia universalis. Partial response to tofacitinib. Med Clin (Barc). 2019;153(3):e15.
103.
Borg MA, Shalabi RA, Childs R, Wells BC. Alopecia universalis and chronic graft-vs-host disease treated with ruxolitinib. JAMA Dermatol. 2018;154(11):1357–8.PubMedPubMedCentralCrossRef
104.
105.
Brown L, Skopit S. An excellent response to tofacitinib in a pediatric alopecia patient: a case report and review. J Drugs Dermatol. 2018;17(8):914–7.PubMed
106.
Cheng MW, Kehl A, Worswick S, Goh C. Successful treatment of severe alopecia areata with oral or topical tofacitinib. J Drugs Dermatol. 2018;17(7):800–3.PubMed
107.
Shin JW, Huh CH, Kim MW, et al. Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: a retrospective study. Acta Derm Venereol. 2019;99(1):41–6.PubMed
108.
Won Y-Y, Loh S-H, Lew B-L, Sim W-Y. The efficacy and safety of tofacitinib in patients with alopecia totalis. J Am Acad Dermatol. 2018;79(3):AB285.CrossRef
109.
Bitterman A, Jabbari A, Chen J, et al. Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata. J Investig Dermatol. 2017;138(5):S77.CrossRef
110.
Scheinberg M, de Lucena Couto Océa RA, Cruz BA, Ferreira SB. Brazilian experience of the treatment of alopecia universalis with the novel antirheumatic therapy tofacitinib: a case. Rheumatol Ther. 2017;4(2):503–8.PubMedPubMedCentralCrossRef
111.
McKesey J, Blankenship DW, Jamison M, DeWitt C. Alopecia universalis successfully treated with tofacitinib. J Am Acad Dermatol. 2017;76(6):AB38.CrossRef
112.
Jabbari A, Cerise J, Chen JC, et al. An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata. J Invest Dermatol. 2017;137(5):S.CrossRef
113.
Jabbari A, Cerise J, Chen JC, et al. An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata. J Investig Dermatol. 2016;136(5):S49.CrossRef
114.
Hosking AM, Juhász M, Mesinkovska NA. Suspected herpes zoster-associated encephalitis during treatment with oral tofacitinib in alopecia universalis. Int J Trichol. 2018;10(6):286–8.CrossRef
115.
Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745.e19–753.e19.CrossRef
116.
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–6.PubMedCrossRef
117.
de Oliveira AB, Alpalhão M, Filipe P, Maia-Silva J. The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review. Dermatol Ther. 2019;5:e13053.
118.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.PubMedPubMedCentralCrossRef
119.
Kahn J, Deverapalli SC, Rosmarin D. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases. Semin Cutan Med Surg. 2018;37(3):198–208.PubMedCrossRef
120.
Cinats A, Heck E, Robertson L. Janus kinase inhibitors: a review of their emerging applications in dermatology. Skin Ther Lett. 2018;23(3):5–9.
121.
Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535–44.PubMedCrossRef
122.
123.
Kostovic K, Gulin SJ, Mokos ZB, Ceovic R. Tofacitinib, an oral Janus kinase inhibitor: perspectives in dermatology. Curr Med Chem. 2017;24(11):1158–67.PubMedCrossRef
124.
Samadi A, Ahmad Nasrollahi S, Hashemi A, Nassiri Kashani M, Firooz A. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. J Dermatol Treat. 2017;28(6):476–83.CrossRef
125.
Nguyen HL, Anderson KR, Tollefson MM. New and emerging therapies for pediatric atopic dermatitis. Paediatr Drugs. 2019;21(4):239–60.PubMedCrossRef
126.
He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–92.PubMedCrossRef
127.
Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205–13.PubMedCrossRef
128.
Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatol Treat. 2019;31:1–8.
129.
Relke N, Gooderham M. The use of Janus kinase inhibitors in vitiligo: a review of the literature. J Cutan Med Surg. 2019;23(3):298–306.PubMedCrossRef
130.
Crowley EL, Fine SC, Katipunan KK, Gooderham MJ. The use of Janus kinase inhibitors in alopecia areata: a review of the literature. J Cutan Med Surg. 2019;23(3):289–97.PubMedCrossRef
131.
Triyangkulsri K, Suchonwanit P. Role of Janus kinase inhibitors in the treatment of alopecia areata. Drug Des Dev Ther. 2018;12:2323–35.CrossRef
132.
Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK inhibitors for treatment of alopecia areata. J Investig Dermatol. 2018;138(9):1911–6.PubMedCrossRef
133.
Iorizzo M, Tosti A. Emerging drugs for alopecia areata: JAK inhibitors. Expert Opin Emerg Drugs. 2018;23(1):77–81.PubMedCrossRef
134.
Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.PubMedCrossRef
Metadata
Title
Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
Authors
Ana M. Montilla
Francisco Gómez-García
Pedro J. Gómez-Arias
Jesús Gay-Mimbrera
Jorge Hernández-Parada
Beatriz Isla-Tejera
Juan Ruano
Publication date
01-12-2019
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 4/2019
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-019-00329-y

Other articles of this Issue 4/2019

Dermatology and Therapy 4/2019 Go to the issue

Original Research

Use of Topical Nitric–Zinc Complex Solution to Treat Palmoplantar and Periungual Warts in a Pediatric Population

Original Research

Erythema of Rosacea Affects Health-Related Quality of Life: Results of a Survey Conducted in Collaboration with the National Rosacea Society

Review

Management of Itch in the Elderly: A Review

Brief Report

Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Children’s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis

Original Research

Local Management of Anogenital Warts in Non-immunocompromised Adults: A Systematic Review and Meta-analyses of Randomized Controlled Trials

Review

Epidemiology, Diagnosis, and Treatment of Atopic Dermatitis in the Developing Countries of Asia, Africa, Latin America, and the Middle East: A Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits